Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Receivables - Net: 2013-2024

Historic Receivables - Net for Ocular Therapeutix (OCUL) over the last 12 years, with Dec 2024 value amounting to $32.4 million.

  • Ocular Therapeutix's Receivables - Net rose 1.76% to $30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year increase of 1.76%. This contributed to the annual value of $32.4 million for FY2024, which is 23.72% up from last year.
  • As of FY2024, Ocular Therapeutix's Receivables - Net stood at $32.4 million, which was up 23.72% from $26.2 million recorded in FY2023.
  • In the past 5 years, Ocular Therapeutix's Receivables - Net ranged from a high of $32.4 million in FY2024 and a low of $12.3 million during FY2020.
  • Over the past 3 years, Ocular Therapeutix's median Receivables - Net value was $26.2 million (recorded in 2023), while the average stood at $26.6 million.
  • Data for Ocular Therapeutix's Receivables - Net shows a peak YoY surged of 380.85% (in 2020) over the last 5 years.
  • Over the past 5 years, Ocular Therapeutix's Receivables - Net (Yearly) stood at $12.3 million in 2020, then soared by 72.50% to $21.1 million in 2021, then rose by 0.90% to $21.3 million in 2022, then climbed by 22.76% to $26.2 million in 2023, then increased by 23.72% to $32.4 million in 2024.